This is the site title that appears in the top of the browser. Search engines place a great deal of emphasis on this tag and it's relevance. A well thought out title can make a real difference to your search engine rankings!

Keywords are becoming less and less important, as search engines try and find more accurate ways of indexing your site and judging its relevance. However, a small number of well known engines still make use of this meta tags, so it should not be ignored completely. Your keywords should be a comma separated list of words and phrases (with a space after the comma). Try not to use more than around 30 words or phrases.

Provided your description is considered by the search engines to be relevant to the content found on your site, then it will be displayed alongside your link in the search results. Again, the key to a good description is relevance. Try to include phrases used early on it your sites text, but also keep it brief - less than 250 characters.

For the most part, this option should be left as 'Please select'. It only needs to be changed if you wish your page to be displayed as part of a submenu. In this instance, simply select the page that will act as the parent of the submenu.

The page title serves 3 purposes. Firstly, it will be displayed at the top of the page. Formatting is taken care of automatically. Secondly, it will be displayed on the menu as the name of the link. Lastly, it will form the link itself. Because of this, try and avoid using any special characters in page titles. For example, rather than using an ampersand '&' type the word 'and'. This should avoid any problems when linking to pages. If you need to link to a page from within your content, you should link to the page title all in lowercase with all spaces replaced by hyphens. The link should always start with a forward slash. So to link to a page titled 'About us' you would link to '/about-us'.

This option will generally not need to be changed. This gives you the ability to insert custom objects such as forms onto your page that have been written for you.

VaccIne Products

 


NATURE OF BUSINESS

Vaccine Products

STAGE OF DEVELOPMENT

Product development and testing

INVESTMENT BEING SOUGHT

£1m of a £5m package

20% EIS TAX RELIEF POTENTIALLY AVAILABLE

Yes

PREPARED TO HAVE MULTIPLE INVESTORS

Yes (Syndicate to be created on request)

INVEST ALONGSIDE VENTURE CAPITAL FUND

Yes (Angel-VC Fund co-investment is expected)

EQUITY STAKE

Negotiable

INVESTOR PARTICIPATION

Non-exec or part-time

MANAGERIAL SKILLS SOUGHT

Financial. Strategic.

LOCATION

Currently based in West Midlands

 

The company specialises in bringing vaccines for worldwide infections to the stage of completion of efficacy trials, when they are licensed to third parties for final tests, manufacture and sale. The Board and the management team have many years experience of research in vaccines and vaccine development, together with experience of the growth and funding of early stage fast growth companies to Stock Exchange listing.

 

The first product is a Staphylococcus aureus vaccine that targets the high costs and deaths from Hospital Acquired Infections (HAI), particularly Methicillin Resistant Staphylococcus aureus (MRSA). Theirs is an innovative "whole organism" vaccine, for which the company is the owner of the patent for the preparation method.

 

These infections are mostly hospital-acquired, but worryingly they are becoming increasingly community-acquired. They are at present estimated to cost health organisations $4.5 bn p.a. in the US and £1bn p.a. in the UK.

 

Significantly, this vaccine is aimed at prevention, and thereby at cutting costs in the healthcare sector. It will be given to patients expecting to be hospitalised, pre-surgery and renal patients, and to recipients of long-term care. The vaccine will also target the carriage of the virus, especially in healthcare workers. 

 

The Company now seeks funding to advance pre-efficacy studies. Reflecting the Board's experience, an exit route for investors will be provided through a public listing in 2008/9 or 2010 that will enable the Company to fund further studies and the development of other vaccines. 

 

 

Further information: Harry Stott, University of Warwick Science Park Limited

 024 7632 3123 or capital@uwsp.co.uk

 

 

Investment in new business carries high risks as well as the possibility of high rewards.  It is highly speculative and potential investors should be aware that no established market exists for the trading of shares in private companies.  Before investing in a project about which information is given, potential investors are strongly advised to take advice from a person authorised under the Financial Services and Markets Act 2000 ("FSMA") who specialises in advising on investments of this kind.  The University of Warwick Science Park Limited ("UWSP") is not authorised to arrange transactions or circulate offer documents under FSMA and cannot advise on the merits or risks of investment.                              

070516